Pregabalin is now fully funded

Pregabalin is a gabapentinoid that is now fully funded and indicated as an option for patients with neuropathic pain, as well as focal seizures and generalised anxiety (unlicensed). Pregabalin may offer advantages over gabapentin in patients where adherence to a three-times-daily regimen is problematic or where gastrointestinal absorption may be impaired. The efficacy of gabapentinoids should be reviewed after initiation and dose escalations, as many patients obtain minimal benefit but experience adverse effects. Gabapentinoids also have the potential to be abused. For more information, see the bulletin published by the CDHB Analgesic Stewardship Committee on our website.

New classes of drugs fully funded from 1st Oct 2018: vildagliptin and sacubitril/valsartan

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes. See BPAC article for further information.
Sacubitril/valsartan is approved for the treatment of symptomatic chronic heart failure with LVEF ‚ȧ40%. Sacubitril is a neprilysin inhibitor (inhibits breakdown of natriuretic peptides increasing diuresis, natriuresis, and vasodilation) and valsartan is an angiotensin-2 receptor blocker. See NZF and American College of Cardiology’s expert analysis for further information.

Upcoming bulletins:

  • CAM: St John’s wort
  • Repackaging of dabigatran into compliance packs